Stock Information
Stock Symbol: TRXB
Stock Exchange: NASDAQ
Company Name: TRex Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Business Focus: Clinical-stage biotechnology focused on tissue regulatory T-cell biology, immune regulation, autoimmune diseases, inflammatory diseases and tissue repair.
Analysis Basis: TRXB is analyzed using the supplied 1-minute chart, EMA20, EMA50, EMA100, RSI, RVOL, CMF, buying pressure, breakout structure, support, resistance and technical price targets.
Quick Technical Snapshot
$14.48
Current Chart Price
$14.76
Visible High
$13.52
Visible Bottom
70 / 100
Breakout Score
- Displayed Open: $14.14
- Displayed High: $14.76
- Displayed Low: $14.14
- Displayed Close: $14.48
- Displayed Candle Change: +2.37%
- Current Price: $14.48
- Visible High: $14.76
- Visible Bottom: $13.52
- Breakout Score: 70 / 100
- Bottom Score: 30 / 100
- RSI: 79.8
- RVOL: approximately 2.6×
- CMF: approximately +0.18
- Buy / Sell Ratio: approximately 1.0×
- Last Bottom: $13.72
- Breakout Midpoint: $14.45
- Breakout Stop: $14.14
- Breakout Price: $14.29
- Target 1: $14.86
- Target 2: $15.25
- Required Volume: approximately 2.64K
EMA Recovery Stage: 3 / 5
The supplied dashboard places TRXB at Stage 3 of 5.
The technical condition is classified as strong recovery / early bullish reversal.
Price has successfully reclaimed:
- EMA20
- EMA50
- EMA100
The next major stage is EMA200.
According to the dashboard, EMA200 recovery remains pending, so the longer-term recovery sequence is not yet fully complete.
Key EMA Levels
$13.99
EMA20
$13.83
EMA50
$13.77
EMA100
Pending
EMA200 Stage
TRXB is currently trading above EMA20, EMA50 and EMA100.
This represents a significant short-term technical improvement.
The current moving-average structure is:
- EMA20: approximately $13.99
- EMA50: approximately $13.83
- EMA100: approximately $13.77
Holding above these moving averages would help preserve the current recovery structure.
Breakout Price: $14.29
The dashboard identifies $14.29 as the main breakout price.
The current price near $14.48 is already above this technical level.
This means TRXB has moved into the breakout zone according to the supplied model.
Holding above $14.29 would help confirm that buyers remain in control.
Breakout Midpoint: $14.45
The breakout midpoint is approximately $14.45.
TRXB is trading near $14.48, placing price just above this important level.
Holding above $14.45 would be constructive, while repeated closes below it could indicate momentum cooling.
Breakout Failure Level: $14.14
The technical dashboard identifies approximately $14.14 as the breakout stop or failure reference.
This level is particularly important because it is also near the low of the current breakout candle.
A sustained decline below $14.14 would materially weaken the short-term bullish structure.
TRXB Support, Resistance and Price Targets
Support Levels
- $14.45 — breakout midpoint
- $14.29 — breakout level
- $14.14 — breakout failure level
- $13.99 — EMA20
- $13.83 — EMA50
- $13.77 — EMA100
- $13.72 — last bottom reference
- $13.52 — major visible bottom
Resistance Levels
- $14.76 — immediate visible high
- $14.86 — target 1
- $15.00 — psychological resistance
- $15.25 — target 2
- $15.50 — possible extension zone
Technical Roadmap
- Hold: $14.45
- Breakout Base: $14.29
- Recent High: $14.76
- Target 1: $14.86
- Psychological Level: $15.00
- Target 2: $15.25
TRXB Target 1: $14.86
The supplied breakout model shows $14.86 as the first technical target.
This level is located just above the current visible high near $14.76.
A breakout above $14.76 with strong volume could quickly place $14.86 into focus.
TRXB Target 2: $15.25
The second displayed target is approximately $15.25.
Before reaching this level, TRXB would first need to overcome the psychological $15.00 area.
A sustained move above $15 with elevated volume would substantially improve the continuation setup.
RSI: 79.8 – Overbought Warning
The dashboard shows RSI near 79.8.
This indicates very strong momentum, but it also places TRXB in a technically overbought condition.
An RSI above 70 does not automatically mean the stock must decline. Strong momentum stocks can remain overbought during powerful advances.
However, the elevated RSI increases the probability of volatility, profit-taking or a short-term pullback.
Relative Volume – RVOL: 2.6×
The dashboard displays relative volume near 2.6×.
This is an important bullish factor because trading activity is significantly above the comparison baseline.
Higher-than-normal volume can provide stronger confirmation for breakout moves.
If RVOL remains elevated while TRXB clears $14.76-$14.86, the continuation setup would become stronger.
CMF Money Flow: +0.18
CMF is approximately +0.18.
This indicates positive money flow and suggests that accumulation has exceeded distribution during the measurement period.
Positive CMF combined with elevated RVOL supports the current bullish structure.
Buying Power vs Selling Power
The dashboard shows a buy-to-sell ratio near 1.0×.
This indicates that buying and selling pressure are approximately balanced.
A move substantially above 1.0× would strengthen the bullish continuation case.
Breakout Score: 70 / 100
The supplied model gives TRXB a breakout score of 70 / 100.
Positive factors include:
- Price above EMA20.
- Price above EMA50.
- Price above EMA100.
- Price above the $14.29 breakout level.
- RVOL near 2.6×.
- CMF near +0.18.
- Strong upward price expansion.
- Current price above the $14.45 midpoint.
Main caution factors:
- RSI is elevated near 79.8.
- EMA200 stage remains pending.
- Moving-average alignment is not yet fully complete.
- Buy / sell ratio is only around 1.0×.
About TRex Bio, Inc.
TRex Bio, Inc. is a clinical-stage biotechnology company focused on regulatory T-cell biology.
The company's research centers on tissue regulatory T cells, also known as Tregs.
TRex Bio aims to develop immunoregulatory medicines designed to restore immune balance and promote tissue repair.
TRex Bio trades on Nasdaq under the ticker TRXB.
Deep Biology Platform
TRex Bio has developed a discovery platform known as Deep Biology.
The platform studies regulatory T-cell function inside human tissue and attempts to identify the biological drivers of immune dysregulation.
This research can support target discovery, drug development and translational research.
TRB-061
One of TRex Bio's key programs is TRB-061.
TRB-061 is an investigational TNFR2 agonist designed to activate and expand regulatory T cells.
Clinical progress and additional study data could become important catalysts for TRXB investors.
TRex Bio Pipeline
- TRB-061 — TNFR2 agonist program.
- TRB-071 — CD30 agonist program.
- TRB-051 — partnered development program.
Pipeline advancement, clinical data and partnership milestones are important fundamental events for the company.
Potential Catalysts
- New TRB-061 clinical data.
- Advancement of TRB-071.
- Progress of partnered TRB-051.
- New pharmaceutical partnerships.
- Positive safety data.
- Positive efficacy data.
- Increasing institutional interest.
- Holding above $14.29.
- Break above $14.76.
- Move toward $14.86.
- Break above $15.00.
- Move toward $15.25.
Major Risk Factors
- Newly listed stock volatility.
- Clinical-stage biotechnology risk.
- Clinical trial failure risk.
- Regulatory risk.
- High research and development spending.
- Potential future shareholder dilution.
- Competition in biotechnology.
- Limited public trading history.
- RSI currently near overbought levels.
- Rapid momentum reversals.
Bullish Scenario
- TRXB holds above $14.45.
- Price remains above $14.29.
- RVOL remains elevated.
- CMF remains positive.
- Price breaks the $14.76 high.
- TRXB reaches $14.86.
- Price clears $15.00.
- Momentum continues toward $15.25.
Neutral / Consolidation Scenario
TRXB may consolidate between approximately $14.00 and $14.76.
A healthy consolidation would ideally keep price above the $14.00-$14.29 region while RSI cools and volume remains constructive.
Bearish Scenario
The first technical warning would be a move below $14.45.
A decline below $14.29 would weaken the breakout.
A sustained break below $14.14 would materially damage the current momentum structure.
Further weakness could expose $13.99, $13.83, $13.77, $13.72 and eventually $13.52.
Trader's Decision Map
Stronger Setup
Hold $14.45 → break $14.76 → RVOL stays elevated → target $14.86 → clear $15.00 → target $15.25.
Wait
Price consolidates between $14.00 and $14.76 while RSI cools and support develops.
Weak Setup
Lose $14.29 → break $14.14 → lose $14.00 → move toward $13.83-$13.72 → potentially $13.52.
Potential Trading Plan
- Current Price: $14.48
- Breakout Midpoint: $14.45
- Breakout Level: $14.29
- Breakout Failure: $14.14
- EMA20: $13.99
- EMA50: $13.83
- EMA100: $13.77
- Last Bottom: $13.72
- Major Visible Bottom: $13.52
- Immediate High: $14.76
- Target 1: $14.86
- Psychological Resistance: $15.00
- Target 2: $15.25
SEO Keywords
Primary Keywords:
TRXB stock,
TRex Bio,
TRex Bio Inc,
TRXB stock analysis,
TRXB stock today,
TRXB stock price,
TRXB stock forecast,
TRXB stock prediction,
TRex Bio stock,
NASDAQ TRXB.
Technical Analysis Keywords:
TRXB technical analysis,
TRXB support and resistance,
TRXB breakout,
TRXB EMA20,
TRXB EMA50,
TRXB EMA100,
TRXB RSI,
TRXB RVOL,
TRXB CMF,
TRXB volume analysis,
TRXB price target,
TRXB breakout level,
TRXB chart analysis.
Company Keywords:
TRex Bio biotechnology,
TRexBio stock,
TRex Bio Treg,
TRB-061,
TRB-071,
TRB-051,
Treg therapeutics,
immunology biotech stock,
autoimmune disease stock,
clinical stage biotech stock.
Long-Tail Keywords:
TRXB stock analysis today,
TRex Bio stock analysis,
TRXB stock support and resistance,
TRXB stock price target,
TRXB breakout level,
TRXB stock forecast 2026,
TRXB technical analysis today,
TRXB stock latest news,
TRex Bio stock,
TRB-061 clinical trial.
Final Conclusion
TRXB currently shows a strong early breakout structure with a breakout score of 70 / 100.
The stock is trading near $14.48, above the displayed breakout price near $14.29 and slightly above the breakout midpoint near $14.45.
RVOL near 2.6× shows strong market participation, while CMF near +0.18 shows positive money flow.
The stock has also recovered above EMA20, EMA50 and EMA100.
The primary momentum warning is RSI near 79.8, which indicates an overbought condition and increases short-term pullback risk.
The immediate visible resistance is approximately $14.76.
A clean break above $14.76 could open the path toward $14.86, $15.00 and the second model target near $15.25.
On the downside, the first important technical references are $14.45, $14.29 and $14.14.
Overall, TRXB currently has strong breakout momentum, elevated relative volume and positive money flow, but traders should closely monitor the elevated RSI and the ability of price to hold above the $14.29-$14.45 breakout region.
Disclaimer: This content is for informational purposes only and does not represent financial advice, a buy recommendation or a sell recommendation.
Available in the USA